Kornimate/medical-research-clean huggingface dataset:
efficacy and safety evaluation of inhaleen inhalation in hospitalized covid-19 patients

Conditions: Covid19

Summary: the current study will investigate the tolerability and efficacy of inhaled carragelose® versus saline in hospitalized covid-19 patients. as sars-cov-2 replicates readily in the lung, it is planed to apply carragelose® in an inhalative form. hospitalized covid-19 patients with respiratory symptoms will inhale inhaleen for 5 days.

the tolerability and efficacy of inhaled carragelose® will be investigated in a randomized, double blind, placebo-controlled trial in hospitalized covid-19 patients. patients will inhale inhaleen or placebo 3 times a day for 7 minutes for 5 days. the primary objective of the trial is to demonstrate that inhaleen inhalation improves the clinical status of hospitalized covid-19 patients on day 8 compared to placebo inhalation.

Eligibility criteria:
inclusion criteria: * written informed consent obtained before any trial related procedures are performed * age ≥ 18 years * hospitalized patients with pcr confirmed sars-cov-2 infection and symptom onset ≤ 10 days before randomization * patients with respiratory covid-19 symptoms * randomization ≤ 48h from admission * peripheral capillary oxygen saturation (spo2) ≥ 90% on room air or supplemental oxygen at screening * patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges) exclusion criteria: * no informed consent * persistent hypoxemia with spo2 \ 6lo2/min at screening. * patients with predominantly extrapulmonary covid-19 symptoms (e.g. gastrointestinal, neurological, etc.) * subjects who demonstrate respiratory and/or cardiac instability that is considered by the investigator as a reason for exclusion. additionally, any other clinically significant disease that could interfere with participation in the study, with the intervention being studied, or with the evaluation of symptoms. specific exclusions are asthma, immune deficiency, autoimmune disease, clinically significant cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or any disease that is considered by the investigator as a reason for exclusion. * known hypersensitivity or allergy to any component of the test product * the subject is related to any study personnel or has any other close ties or conflicts of interest with the study sponsor. * the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study * current medication other than oral contraception,that is considered by the investigator as a reason for exclusion. * pregnant/lactating women at the time of recruitment will be excluded from the study * participation in another antiviral clinical trial

Keywords: carragelose iota-carrageenan lung virus respiratory virus inhalation common cold
early pancreatic duct stent removal in preventing post-endoscopic pancreatitis

Conditions: Acute Pancreatitis

Summary: temporary pancreatic duct stent placement during endoscopic retrograde cholangiopancreatography (ercp) has been recommended for post-endoscopic pancreatitis (pep) prophylaxis in high risk patients, including those in whom accidental pancreatic duct cannulation has occurred. however, the optimal duration of stent placement remains an open question. the investigators aim is to assess if immediate stent removal is effective in the prevention of pep after accidental pancreatic duct cannulation.

recent meta-analyses of randomized controlled trials confirmed that pancreatic stent placement after ercp reduces the risk of pep but the optimal duration of stent placement remains an open question. it has been suggested that in truly high-risk patients the pancreatic stent must be left in place for a minimum of 24 hours or more whereas in patients at lesser risk pancreatic duct drainage probably only needs to be maintained for a few hours or less. leaving the stent in place at the end of the ercp procedure carries the disadvantage of radiological follow-up until spontaneous dislodgment occurs or endoscopic removal is deemed timely; moreover, proximal migration has been reported, requiring endoscopic or even surgical removal. there is a paucity of data comparing immediate removal with spontaneous dislodgment in high-risk patients. in one study, significantly higher rates of pep were detected in patients in whom a pancreatic stent was removed immediately at the end of the ercp procedure than in those in whom the stent was left in place: unfortunately, only patients undergoing a precut sphincterotomy were evaluated in that study which was published only in abstract form. therefore, it is still uncertain whether leaving a stent in place is more effective than immediate removal in preventing pep in high-risk patients.

Eligibility criteria:
inclusion criteria: * all patients in whom accidental pancreatic duct cannulation had occurred * during guide wire directed ercp exclusion criteria: * patients who had undergone previous endoscopic papillectomy or sphincterotomy * and those with an indwelled nasobiliary or nasopancreatic tube

Keywords: pancreatic duct stenting post-endoscopic pancreatitis
effect of oral collagen tripeptide on skin moisture and wrinkles in adult women

Conditions: Skin Manifestations; Skin Wrinkling

Summary: comparison of a randomized, double-blind, and control-group study for the effect of oral ingestion of collagen tripeptides derived from fish on dermal moistures and wrinkles body fat reduction in participants

the aim is to investigate the effect of oral ingestion of collagen tripeptides derived from fish on dermal moistures and wrinkles body fat reduction in participants by a randomized, double-blind, and control-group study.

Eligibility criteria:
inclusion criteria: - \> = 4 of tewameter exclusion criteria: * within the last 6 months, took skin surgery including cosmetic purpose * diabetic patients with poor glycemic control with a fasting blood glucose of 160 mg/dl or more * creatinine levels: more than twice the normal upper limit * ast (got) or alt (gpt) levels: more than twice the normal upper limit * uncontrolled hypertension * sun allergy or sensitive skin * functional cosmetics that affect dermal moistures and wrinkles within the last 3 months. * if you have participated or are planning to participate in another clinical trial within the past month * alcohol abuser * if they are pregnant or lactating or have a pregnancy plan during the clinical trial those with allergic reactions to the constituent food * any person deemed inappropriate by the researcher for other reasons
what are the predictive factors for preeclampsia in oocyte recipients? - prerove

Conditions: Pregnancy; Oocyte Donation

Summary: the main goal is to determine which risk factors develop preeclampsia in this specific group of oocyte recipients.


Eligibility criteria:
inclusion criteria: * all major patients with a pregnancy of more than 22 weeks of amenorrhea resulting from an oocyte donation in one of the study centers, having given birth between january 2010 and april 2017 and not opposed to participation in the study. exclusion criteria: * all pregnancies resulting from an oocyte donation abroad, persons of legal age subject to legal protection (safeguard of justice, guardianship, tutorship) and persons deprived of their liberty.
re-hospitalized patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the predictors of re-hospitalization of patients with history of acute coronary syndrome

the aim of this retrospective multicenter study is to evaluate the demographic, clinical characteristics and medications of re-hospitalized for new cardiac event in patients with history of acute coronary syndrome within in 12 months.

Eligibility criteria:
inclusion criteria: patients age \>18 years who had hospitalized for acute coronary syndrome within 12 months exclusion criteria: patients whose previous hospitalizations data are not available myocardial infarction, type 2 patients

Keywords: myocardial infarction hospitalization coronary artery disease retrospective cohort study
hl2351 caps phase ii study

Conditions: Cryopyrin-Associated Periodic Syndromes (CAPS)

Summary: this is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of hl2351 in patients with cryopyrin associated periodic syndromes (caps).

this trial enrolls patients with caps being on stable dose of anakinra daily and then switch over hl2351 given once weekly. it consists of 4 phases, 6-week screening, single dose pk, 6-month multiple dose, and 18-month extension phase.

Eligibility criteria:
inclusion criteria: * documented molecular diagnosis of nalp3 mutation or diagnosis of caps based on sign and symptom * diagnosis of caps based on signs and symptoms * current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids exclusion criteria: * patient been diagnosed with a hereditary periodic fever syndrome or autoinflammatory disease other than caps * patients whose disease is inadequately controlled on current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids

Keywords: auto-inflammatory diseases il-1 inhibitors hl2351 cryopyrin-associated periodic syndromes (caps) neonatal onset multisystem inflammatory disease (nomid) muckle-wells syndrome (mws) familial cold autoinflammatory syndrome (fcas)
a trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors

Conditions: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors

Summary: this trial is conducted in africa, asia, europe and north america. the aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia a and b patients with inhibitors.


Eligibility criteria:
inclusion criteria: - informed consent obtained before any trial related activities. trial related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - male haemophilia a or b patients with inhibitors aged 18 years or older at the time of signing informed consent - patients currently in need of treatment with bypassing agents exclusion criteria: - known or suspected hypersensitivity to trial product(s) or related products - known inherited or acquired bleeding disorder other than haemophilia - ongoing or planned immune tolerance induction therapy or prophylaxis with fviii or fix
vascular anomaly pathology and genomics biopsy study

Conditions: Vascular Malformations; Vascular Anomaly; Hemangioma; Arteriovenous Malformations; Venous Malformation; Klippel Trenaunay Syndrome; Lymphatic Malformation

Summary: the purpose of this research is to gather information on the safety and effectiveness of core biopsy of vascular anomalies for clinical pathology and clinical genomics studies.

vascular anomalies or vascular malformations often are treated with minimally invasive sclerotherapy, embolization or ablation based on clinical and imaging features without acquisition of tissue. over the last two decades there have been significant advancements in the understanding of the genetic basis for various vascular anomalies/malformations, which may guide use of therapies for individualized treatment. as such, given the emergence of novel medications for treatment of vascular anomalies/malformations based on genetic information, acquisition of tissue for pathology and genomic characterization will be increasingly important as treatment of vascular anomalies/vascular malformations moves toward individualized medicine approach.

Eligibility criteria:
inclusion criteria: * patients with a clinical and imaging diagnosis of a vascular anomaly. * no prior treatment for the vascular anomaly. * subjects undergoing clinically indicated sclerotherapy, embolization and/or ablation. * male or female with age greater than or equal to 18 years. * capacity and willingness to provide a written informed consent.. exclusion criteria: * subjects with prior treatment for their vascular anomaly. * uncorrectable coagulopathy. * pregnant and/or breast-feeding subjects. a negative pregnancy test within 48 hours of the procedure.
study of the effectiveness of telmisartan in slowing the progression of abdominal aortic aneurysms

Conditions: Abdominal Aortic Aneurysm

Summary: the purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of abdominal aortic aneurysms (aaa) biomarkers.

currently, the only management options for aaa are surgical (open or endovascular) based on ongoing follow-up with imaging at regular intervals. telmisartan is currently approved for use in the united states by the food and drug administration for management of hypertension. if telmisartan is found to be effective in slowing the progression of abdominal aortic aneurysms, this would provide a new treatment option for patients with aaa disease.

Eligibility criteria:
inclusion criteria: * 50-85 years of age and able to provide written informed consent * aaa measuring a maximum diameter of 3.5-4.9 cm on cta or ultrasound * stable medication regime for the last six months * no current indication for aaa repair according to the treating physician or expectation that this will be revised within the next year * high likelihood of compliance with treatment over 24 months exclusion criteria: * renal impairment (i.e. creatinine \>1.5x upper limit of normal \[uln\]) * known significant renal stenosis (\>70%) of one or both renal arteries * chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. alt 1.5xuln) * electrolyte imbalance * active gout * current or planned usage of an at1 blocker or ace inhibitor * previous abdominal aortic surgery * currently pregnant or intend to become pregnant

Keywords: abdominal aortic aneurysm aaa telmisartan
web based intervention to reduce weight bias among dietitians

Conditions: Intervention Video (I); Weight Control Video (C1); Weight Neutral Control Video (C2)

Summary: weight bias in dietitians is prevalent and may affect patient care. the investigators conducted a randomized controlled trial to test if explicit and implicit bias could be influenced by a short, 20 minute educational video.

this randomized controlled trial studied the effect of three different videos on weight bias in a nationally representative sample of dietitians. the "intervention" group (i) watched a video about the etiology of obesity, reasons for weight regain, and how to talk to patients about weight. the first "control" group (c1) received information about the role of the environment and individual behavior in weight gain, and tools to help patients control their weight. the second control group (c2) received a weight neutral video about the role of dieticians in society. bias measures were taken before and just after watching the video, and again one month later.

Eligibility criteria:
inclusion criteria: * any dietitian in the clinical dietitian registry database. exclusion criteria: * none
effect of end-inspiratory pause on gas exchange during mediastinal mass excision with co2 insufflation and one-lung ventilation

Conditions: Mediastinal Mass Requiring Video-assisted Surgical Excision

Summary: " mediastinal mass excision is typically performed via video-assisted thoracoscopic surgery (vats). to secure a clear surgical field, the ipsilateral lung must be deflated, achieved through one-lung ventilation (olv) and intrathoracic co₂ insufflation. however, olv increases intrapulmonary shunt due to continued perfusion of the non-ventilated lung, potentially leading to hypoxemia and hypercapnia. when performed in the supine position, gas exchange becomes more challenging compared to lateral decubitus due to limited gravitational redistribution of blood flow. although co₂ insufflation aids surgical exposure through passive lung deflation, it may also increase cvp and pcwp, reduce cardiac output, and raise paco₂, contributing to respiratory acidosis. end-inspiratory pause (eip), a ventilatory setting that pauses airflow at end-inspiration, prolongs alveolar gas exchange and improves ventilation-perfusion matching. prior studies show eip can enhance gas exchange, reduce microatelectasis, and improve co₂ clearance in patients with acute lung injury. we therefore aimed to assess the effect of eip application during vats mediastinal mass excicion.


Eligibility criteria:
inclusion criteria: * adult patients aged 20 to 80 years scheduled for video-assisted thoracoscopic mediastinal tumor resection. * american society of anesthesiologists (asa) physical status classification of ii (patients with mild systemic disease) or iii (patients with severe systemic disease limiting activity). exclusion criteria: * moderate to severe chronic obstructive pulmonary disease (copd) according to gold criteria: defined as fev₁/fvc \< 0.7 and fev₁ ≤ 80% of predicted on pulmonary function testing. * diffusion capacity of the lung for carbon monoxide (dlco) \< 80% of predicted. * history of pneumothorax or presence of bullae or blebs on preoperative imaging. * inability to read or understand the subject information sheet and consent form.
rh-endostatin in combination with dacarbazine and cisplatin as the first line therapy for metastatic melanoma

Conditions: Melanoma

Summary: the incidence of melanoma is rapidly growthing,and in china,dacarbazine combined with cisplatin is conmendly used as the first-line chemotherapy of metastatic melanoma. but the response rate and survival results are very limited.this trial aim to add a safe and effective anti-angiogenesis drug,human-recombinant endostatin,to find out a new strategy which may further extend the pfs and os with a tolerated toxicity.


Eligibility criteria:
inclusion criteria: * 1. histologically confirmed melanoma with metastases and has no received any systemic treatment. * 2.at least one measurable site (diameter≥1cm) of disease (recist 1.1). * 3.estimated life expectancy of 12 weeks or greater * 4. ecog performance status 0, 1 * 5.adequate organ function * 6.without symptoms of brain metastases and stable in neuro-functions exclusion criteria: * 1. pregnant or lactation women * 2. acute infections without control. * 3. heart disease history, cardiac function class≥nyha ii. * 4. hiv positive or chronic hbv/hcv in active stage. * 5. brain metastases or primary tumor with positive symptoms * 6. need anti-epileptic treatments * 7. organ transplantation history * 8. hemorrhagic tendency or related history * 9. renal dialysis patients * 10. diagnosis of any second malignancy within the last 3 years, except for adequately treated. * 11. current treatment on another clinical trial * 12. the other improper situations which investigator judged.

Keywords: endostar dacarbazine cisplatin
examining how heart disease risk factors affect healthy aging (the chicago healthy aging study [chas])

Conditions: Coronary Disease; Cardiovascular Diseases

Summary: heart disease is the leading cause of death in the united states and is responsible for 30% of all deaths in the united states. this study will examine how risk factors for heart disease in young and middle aged people affect people's health as they grow older.

heart disease, including coronary heart disease (chd) and cardiovascular disease (cvd), is a serious health problem in the united states. it is the leading cause of death in this country, and each year almost 700,000 people die from the disease. risk factors for heart disease include high blood pressure, high cholesterol levels, tobacco use, diabetes, and history of a prior heart attack. it has been shown that young and middle aged adults with few risk factors experience a lower incidence of heart disease, lower medicare costs, and longer lives than those with more risk factors. however, it is not known how having a low risk for heart disease at a young age affects health-related outcomes in older age. it may be possible that a low risk for developing heart disease in younger years results in healthier aging than does a higher risk. this study will examine former participants of the chicago heart association (cha) study who are now 65 to 84 years old. the purpose of this study is to determine how risk factors for heart disease in young adulthood and middle age are related to healthy aging. this study will enroll 1500 people who participated in the cha study from 1967 to 1973 and who are still living in the greater chicagoland area. six hundred former participants who had a low risk of developing heart disease and 900 former participants who had a high risk of developing heart disease will be enrolled. participants will attend one study visit that will include medical history interviews and questionnaires, a physical examination, blood pressure measurements, blood and urine collection, and an electrocardiogram (ecg) to measure the electrical activity of the heart. blood samples will be collected and stored for future genetic testing. participants will undergo physical functioning performance tests on balance, leg strength and coordination, grip strength, and endurance. they will also undergo a computed tomography chest scan to measure the amount of calcium in the arteries of the heart and ultrasound scans of the arteries in the neck to measure artery size and function.

Eligibility criteria:
inclusion criteria: * participated in the cha study * lives in the greater chicagoland area exclusion criteria: * severely ill, disabled, or cognitively impaired

Keywords: coronary heart disease subclinical atherosclerosis cvd-related markers of inflammation mortality
phase ii study of the effect of ck-1827452 injection on myocardial efficiency

Conditions: Heart Failure

Summary: the purpose for this study (cy 1124) is to evaluate the effects of ck-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of ck- 1827452 is substantially the same in patients with heart failure.


Eligibility criteria:
inclusion criteria: * clinical indication for left and right heart catheterization * willing and able to provide informed consent * male or female 18 years of age or greater * symptomatic heart failure (≥ nyha class ii) * ejection fraction ≤ 35% * patient is in sinus rhythm * patient is considered to be in suitable health in the opinion of the investigator, as determined by: o a pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure * for female patients only: post-menopausal or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant for up to 90 days following the study, and she is using contraceptive drugs or devices exclusion criteria: * acute myocarditis * hypertrophic, restrictive, or constrictive cardiomyopathy * congenital heart disease * known left ventricular thrombus * significant stenotic valvular disease (severe aortic stenosis, mitral stenosis) * poorly controlled hypertension (sbp \> 180 mmhg) * pacemaker dependent ventricular rhythm * detectable troponin or ck-mb \> uln at any timepoint within 14 days of enrollment * acute coronary syndrome or revascularization procedure within 30 days of enrollment * ≥ 50% stenosis of the left main coronary artery * plan for immediate revascularization procedure (pci or cabg) * gfr ≤ 35 ml/min/1.73 m2 by modification of diet in renal disease (mdrd) equation or need for renal replacement therapy * known hepatic impairment (total bilirubin \> 3 mg/dl, or alt and ast \> 2 times the upper limit of normal) * has received an investigational drug or device within 30 days before enrollment * has had any prior treatment with ck-1827452